Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of nirsevimab for prevention of RSV lower respiratory tract infection in healthy preterm and term infants in China
2021-005075-38Phase 3
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Nirsevimab with Placebo (2 arms). Primary endpoint: Incidence of medically attended RSV lower respiratory tract infection.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2021-005075-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005075-38.